ライフサイエンスコーパス: SAE

1 SAE and EAE are frequently studied as models for the hum

2 SAE was significantly associated with future CHD, stroke

3 SAEs associated with hepatic decompensation were the mos

4 SAEs did not significantly affect QoL in emergency lapar

5 SAEs were numerically more frequent in the rituximab gro

6 ed nuclear genes in both parental and rho(0) SAE cells in response to asbestos treatment.

7 l airway epithelial (SAE) cell model: rho(0) SAE cells lack the capacity to produce mitochondrial ROS

8 e effects of asbestos were minimal in rho(0) SAE cells.

9 d related to darapladib, was reported, and 1 SAE of severe diarrhea was reported in a placebo patient

10 recipients with prior HZ who developed >/= 1 SAE (0.95%) was not significantly different from that of

11 Sixteen patients (64%) experienced >/=1 SAE.

12 mary outcome measure was development of >/=1 SAE; secondary outcome measures were death, arteriothrom

13 mab was 1.06 [(0.84, 1.35); p=0.61] for >/=1 SAEs.

14 ght (80%) SOC participants had a total of 11 SAEs compared to 2 (20%) FMT participants with SAEs (bot

15 A total of 143 SAEs occurred in 59 (10.6%) patients; only three events

16 xtract CrVI from environmental matrixes; (2) SAE-SPE to separate CrVI from CrIII and interferences; (

17 compensation were the most frequent, with 26 SAEs occurring in 19 patients (18%).

18 There were 29 SAEs considered to have some relationship with the injec

19 The MAR was similar across the 3 SAEs.

20 (23% of those entering the RCT) reported 39 SAEs.

21 baseline were associated with occurence of a SAE.

22 ciliated and basal cells, markedly abnormal SAE and alveolar macrophage transcriptomes, and elevated

23 re also able to produce S-adenosylethionine (SAE) from substrate ethionine.

24 years, the most frequent ocular serious AE (SAE) and AE were cataract (2.1%) and eye pain (14.6%), r

25 e incidence of study eye ocular serious AEs (SAEs) and SAEs potentially related to systemic vascular

26 Serious AEs (SAEs) occurred infrequently.

27 been placed on the reporting of serious AEs (SAEs) that are either life threatening or lethal in clin

28 day 42 postvaccination and for serious AEs (SAEs) through day 182 postvaccination.

29 roups (90.9% versus 91.5%), but serious AEs (SAEs) were higher in the abatacept group (19.8 versus 6.

30 Serious AEs (SAEs) were recorded through 6 months postvaccination.

31 erse events (AEs) and number of serious AEs (SAEs) were similar across arms.

32 review of adverse events (AEs), serious AEs (SAEs), and new medical conditions for 6 months after FMT

33 rse events (AEs), and sometimes serious AEs (SAEs).

34 Except in 1 patient with cancer, all SAEs resolved after appropriate treatment.

35 Although SAEs are likely to affect QoL, this has not been demonst

36 women were twice as likely to experience an SAE (OR for men, 0.50; P = .005).

37 up tended to be less likely to experience an SAE over the entire 25 months of the study.

38 cted lower airway epithelial cells (A549 and SAE).

39 is not associated with more side effects and SAE.

40 ors examined the prognostic value of LAE and SAE for clinical CVD events among 6,235 Multi-Ethnic Stu

41 LAE and SAE were derived from diastolic pulse contour analysis.

42 for decision making between splenectomy and SAE (AUC, 0.84).

43 nal requirements (2 vs 6 PRBC; P = 0.08) and SAEs lower (15% vs. 47%; P = 0.077) in the esophageal st

44 ilar in both groups, and unsolicited AEs and SAEs were all unrelated to the study vaccines.

45 ystemic reactions, adverse events (AEs), and SAEs were similar in both groups, and unsolicited AEs an

46 There was no correlation between dose and SAEs in any group.

47 t groups, with a slight increase in SAEs and SAEs involving bleeding in the 0.05 mg/kg/hr rTFPI group

48 e of study eye ocular serious AEs (SAEs) and SAEs potentially related to systemic vascular endothelia

49 ing B cells were isolated and yielded 6 anti-SAE clones, 2 each for SEA, SED, and SEE.

50 scribed in adult-onset dermatomyositis (anti-SAE autoantibodies) and juvenile dermatomyositis (anti-p

51 ew period, the clinical associations of anti-SAE and anti-p140 have been further described.

52 ps in which nearly all patients express anti-SAEs.

53 1 year, there were no ventricular arrhythmia SAEs observed among allogeneic recipients compared with

54 Twenty-nine AEs were classified as SAEs and mainly related to immune conditions.

55 ficients for correlation between model-based SAEs and American Community Survey direct estimates of n

56 The model-based SAEs and direct survey estimates of COPD prevalence were

57 ficients for correlation between model-based SAEs and Missouri County-Level Study direct estimates fo

58 egression and poststratification model-based SAEs using single-year Behavioral Risk Factor Surveillan

59 Unweighted and weighted model-based SAEs were compared with direct estimates; unweighted mod

60 Aggregated model-based SAEs were consistent with national prevalence estimates

61 Model-based SAEs were validated against national estimates directly

62 1 score, the mean difference in QoL between SAE and no-SAE patients was 0.140 in esophagectomy, 0.11

63 A novel method was developed by SAE-DLLME for chromium speciation in water and rice samp

64 The most common SAE reported was either conjunctival erosion or dehiscen

65 ired supplemental oxygen was the most common SAE.

66 In conclusion, SAEs after donation are rare but more often occurred in

67 es assessed the combined effect of different SAEs.

68 lasticity (LAE) and small artery elasticity (SAE) may predict cardiovascular disease (CVD) events bey

69 ndicated they are willing to accept elevated SAE risks in exchange for clinical efficacy.

70 1 patient in each group (treatment-emergent SAE rate, 6.7%) was hospitalized for heart failure, less

71 The most common treatment-emergent SAEs included dyspnea, pneumonia, febrile neutropenia, d

72 ociated with low rates of treatment-emergent SAEs, including immunologic reactions.

73 There were no 30-day treatment-emergent SAEs.

74 accine-induced autoimmune encephalomyelitis (SAE) occurs in 1 in 220 immunized individuals.

75 e use of AAVE vs. Standard American English (SAE) is important for policy and scientific reasons.

76 against Staphylococcus aureus enterotoxins (SAEs).

77 AE2 subunit of human SUMO activation enzyme (SAE) underwent rapid nucleocytoplasmic shuttling and its

78 Surface-active artificial enzymes (SAEs) are designed and constructed by a general and nove

79 g fluid metabolome, small airway epithelial (SAE) cell differential and transcriptome, alveolar macro

80 eted (rho(0)) human small airway epithelial (SAE) cell model: rho(0) SAE cells lack the capacity to p

81 ia of smoke-treated small airway epithelial (SAE) cells, respectively.

82 y disease (COPD), a small airway epithelial (SAE) disorder that is a risk factor for non-small cell l

83 The small airway epithelium (SAE), the first site of smoking-induced lung pathology,

84 include a Sharpless asymmetric epoxidation (SAE) of a trans-vinylsilane and an enzymatic resolution

85 mpounds, a Sharpless asymmetric epoxidation (SAE) route yielded in a direct fashion the required comp

86 Such small area estimates (SAEs) often lack rigorous external validation.

87 y flexible to generate small-area estimates (SAEs) to meet data needs at different geographic levels.

88 tes by using a novel, small area estimation (SAE) method.

89 t was the only ocular serious adverse event (SAE) that occurred.

90 of individuals with a serious adverse event (SAE); of these, 33 (87%) reported more SAEs in ClinicalT

91 isease-related (LDR) serious adverse events (SAE) during long-term lamivudine treatment.

92 ne were followed for serious adverse events (SAE) for 28 days after vaccination.

93 of treatment-related serious adverse events (SAE) than patients randomized to standard BP control (<1

94 IS-related serious adverse events (SAE) were reported in 47% of patients, with 4 presenting

95 ividuals at risk for serious adverse events (SAEs) after exposure to ivermectin, using thresholds of

96 ncidence of systemic serious adverse events (SAEs) among patients with neovascular age-related macula

97 cluded the number of serious adverse events (SAEs) and quantification of viral RNA in blood.

98 y measuring rates of serious adverse events (SAEs) and serious infections.

99 Surgical adverse events (SAEs) are associated with poor outcome.

100 vaccine causes rare serious adverse events (SAEs) following immunization.

101 id use and risk of 3 serious adverse events (SAEs) known to be associated with CD treatment (progress

102 disease and vaccine serious adverse events (SAEs) may be imprecise.

103 Overall, 123 serious adverse events (SAEs) occurred in 49 patients (47%).

104 Serious adverse events (SAEs) occurred with similar frequency in treated versus

105 No ocular severe adverse events (SAEs) or SAEs considered related to darapladib were repo

106 ps, the incidence of serious adverse events (SAEs) was 10.1% and 9.1%, respectively, and the rate of

107 erse events (AEs) and severe adverse events (SAEs) was similar among the treatment groups, with a sli

108 No serious adverse events (SAEs) were attributable to study drug, as determined by

109 rate, and number of Serious Adverse Events (SAEs) were compared.

110 The frequencies of severe adverse events (SAEs) were higher in the bevacizumab arm (n = 63) compar

111 Serious adverse events (SAEs) were more common in CTP class B/C versus CTP class

112 Serious adverse events (SAEs) were more common in the renal dysfunction groups t

113 Serious adverse events (SAEs) were reported in 2 rituximab-treated patients (pne

114 were predefined and serious adverse events (SAEs) were reported to ethics committees and a central s

115 FDA definitions for serious adverse events (SAEs) were used, and all events were reviewed by an inde

116 There were 15 serious adverse events (SAEs) with a non-significantly higher percentage occurri

117 d treatment-emergent serious adverse events (SAEs), five of whom had immune-related SAEs, including t

118 ed the incidences of serious adverse events (SAEs), medically important infections (MIIs), and death.

119 ify risk factors for serious adverse events (SAEs), thereby limiting their influence on sedation prac

120 rily vaccine-related serious adverse events (SAEs)--up to 3 months after administration of a single d

121 nts did not have any serious adverse events (SAEs).

122 d treatment-emergent serious adverse events (SAEs).

123 OC using FMT-related serious adverse events (SAEs).

124 bleeding and without serious adverse events (SAEs).

125 subjects (29.0%) had serious adverse events (SAEs).

126 2-months for safety (serious adverse events [SAE]), and efficacy endpoints: ejection fraction, Minnes

127 gram (CARSEP) V Self-assessment Examination (SAE) from 1997 to 2002 were scored and analyzed, includi

128 We examined SAE gene expression in 178 individuals, including health

129 Four outcomes were examined: SAEs, significant interventions performed in response to

130 re subjects in the placebo group experienced SAEs (P = .02).

131 lated in adenocarcinoma versus smoke-exposed SAE.

132 trong anion-exchange solid-phase extraction (SAE-SPE) technique, the filtration, isolation, and deter

133 t outcomes, resulting in significantly fewer SAEs and interventions than ketamine combined with propo

134 , BM donors maintained an increased risk for SAEs (0.99% for BM vs 0.31% for PBSC; OR, 3.20; P < .001

135 BM donors had an increased risk for SAEs (2.38% for BM vs 0.56% for PBSC; odds ratio [OR], 4

136 ients) and a mean 2.2+/-1.2% higher risk for SAEs (range, 0.5%-15.8% more harm in individual patients

137 However, SAEs comprise a small subset of all AE data collected fo

138 ared with nonsmokers, and whether changes in SAE DNA methylation were linked to the transcriptional o

139 ency of HLA-DQ7 (DQB1*0301) was decreased in SAE patients (8%) compared with vaccinated controls (15%

140 and pathological changes of demyelination in SAE suggest that this disease is the human homologue of

141 re found to associate with its expression in SAE.

142 r any CVD per standard-deviation increase in SAE was 0.71 (95% confidence interval: 0.61, 0.83; P < 0

143 ) and HLA-DR17 (DRB1*0301) were increased in SAE patients (DR9 = 22%, DR17 = 14%) compared with vacci

144 04 unique genes differentially methylated in SAE DNA of smokers compared with nonsmokers, with 67% of

145 se in nuclear DNA oxidative damage and MN in SAE cells.

146 aB and proinflammatory signaling pathways in SAE cells.

147 TCRBV alleles and haplotypes were similar in SAE patients and vaccinated controls.

148 treatment groups, with a slight increase in SAEs and SAEs involving bleeding in the 0.05 mg/kg/hr rT

149 eated patients experienced a total of 60 LDR SAEs.

150 ce of hepatic decompensation (0%-2%) and LDR SAEs (1%-10%) among patients with lamivudine resistance

151 ageal stents have greater efficacy with less SAEs than balloon tamponade in the control of EVB in tre

152 ck population to generate census-block-level SAEs of COPD prevalence which could be conveniently aggr

153 ll line [Squalus acanthias embryo cell line (SAE)], a mesenchymal stem cell line derived from the emb

154 as identified the mechanism used to localize SAE to the nucleus.

155 omatic participants free of overt CVD, lower SAE added prognostic information for CVD, CHD, stroke, a

156 uria was significantly associated with lower SAE: relative difference = -6% (95% CI: -10, -1).

157 n C were incrementally associated with lower SAE: third quintile relative difference = -5% (95% confi

158 lTrials.gov, 11 publications did not mention SAEs, 5 reported them as zero or not occurring, and 21 r

159 p-nitrophenolate catalyzed by esterase-mimic SAE.

160 Twelve-month SAE incidence was 28.2% with allo-hMSCs versus 63.5% wit

161 ent lower response rates and experience more SAEs.

162 vent (SAE); of these, 33 (87%) reported more SAEs in ClinicalTrials.gov.

163 Most SAEs were single, disease-related events occurring durin

164 of SAEs was very low, and the nature of most SAEs was manageable, demonstrating a low-risk safety pro

165 No SAEs occurred in the study eye.

166 Notably, no SAEs related to icatibant occurred in patients with card

167 There were no SAEs clearly related to methylprednisolone administratio

168 There were no SAEs related to FMT.

169 ary artery occlusion), whereas there were no SAEs reported in placebo-treated patients.

170 he mean difference in QoL between SAE and no-SAE patients was 0.140 in esophagectomy, 0.110 in the Cr

171 The incidence of nonocular SAEs was 8.8% in the IAI group and 9.8% in the laser gro

172 phthalmitis, and the incidences of nonocular SAEs were low.

173 Using genome-wide methylation analysis of SAE DNA of nonsmokers and smokers, the data identified 2

174 Importantly, we observed a high frequency of SAE in triple therapy, especially in patients with liver

175 leles may have a role in the pathogenesis of SAE and its mechanism may be different from those involv

176 d intermediate cells, reduced proportions of SAE ciliated and basal cells, markedly abnormal SAE and

177 metabolome profile, increased proportions of SAE secretory and intermediate cells, reduced proportion

178 lower in the bevacizumab arm (60% vs 75% of SAEs).

179 story of HZ (0.66%), and the distribution of SAEs in the 2 groups was comparable.

180 Significantly negative effects of SAEs on QoL were demonstrated in a range of procedures.

181 The frequency of SAEs was 5% to 48%.

182 The overall frequency of SAEs was very low, and the nature of most SAEs was manag

183 be a surrogate for the severity of impact of SAEs on patients.

184 The overall impact of SAEs on QoL scores was determined by combining results f

185 evaluate the economic and societal impact of SAEs thereby defining the threshold for safe practice.

186 de alone resulted in the lowest incidence of SAEs (17 [0.4%]) and significant interventions (37 [0.9%

187 cally insignificant increase in incidence of SAEs involving bleeding was observed in the all rTFPI gr

188 The 1-year incidence of SAEs was 33.3% (n = 5) in the allogeneic group and 53.3%

189 5% CI, 2.3-8.7) had the highest incidence of SAEs.

190 e promise to help elucidate the mechanism of SAEs.

191 68% versus 55%; P = 0.30), but the number of SAEs per patient was higher in the treated group (2.7 ve

192 rring, and 21 reported a different number of SAEs.

193 A time-to-event analysis of patterns of SAEs indicated that subjects in the periodontal therapy

194 allowed adjustment for strong predictors of SAEs.

195 The overall rate of SAEs (0.12 per patient-year) did not increase with long-

196 The increased rate of SAEs requires further assessment.

197 The rate of SAEs was 0.13 per patient-year, and the rate of serious

198 with long-term use of ranibizumab; rates of SAEs potentially related to treatment were consistent wi

199 At present, the mechanism(s) of SAEs is(are) poorly understood but our advances in under

200 High-density microarrays performed on SAE cells confirmed a similar pattern of RSV-inducible e

201 Individual patient data on SAEs, assigned drug and dosing regimen, and baseline pro

202 One SAE of myocardial infarction, not considered related to

203 Twenty-one SAEs and 2 deaths were reported, all assessed by investi

204 No ocular severe adverse events (SAEs) or SAEs considered related to darapladib were reported.

205 Overall SAE rates were 23.09 (control) and 20.80 (IAI); overall

206 multilevel regression and poststratification SAEs from 2011 Behavioral Risk Factor Surveillance Syste

207 the same catalytic site to form the product SAE.

208 to SAEs and determine whether they recognize SAEs through their complementarity-determining regions (

209 338 patients (3.6%) had a treatment-related SAE during a median follow-up of 3.3 years.

210 risk for MACE or death and treatment-related SAE to allow for individualized BP treatment goals based

211 overdoses accounted for 25 of the 29 related SAEs.

212 ents (SAEs), five of whom had immune-related SAEs, including two with adrenal insufficiency, two with

213 No product-related SAEs were observed.

214 isk factors associated with sedation-related SAEs.

215 No vaccine-related SAEs occurred during the 3 months of follow-up of 4004 s

216 compared to placebo, and no vaccine-related SAEs or deaths.

217 national health surveys to generate reliable SAEs for population health outcomes at all administrativ

218 Among the 84 trials that reported SAEs in ClinicalTrials.gov, 11 publications did not ment

219 The proportion of subjects reporting SAEs occurring within 42 days postvaccination (ZV, 0.6%;

220 Thirty-seven SAE-specific, IgG- or IgA-expressing B cells were isolat

221 A, SED, and SEE were used to isolate single SAE-specific B cells from the nasal polyps of 3 patients

222 tion rate (GFR), and albuminuria with small (SAE) and large (LAE) arterial elasticity and aortic dist

223 gG1, and those of high affinity for specific SAEs, assayed by means of ELISA and surface plasmon reso

224 The lowest (stiffest) SAE quartile had a hazard ratio of 2.28 (95% confidence

225 g postoperative QoL in patients who suffered SAEs were identified.

226 kens, in which speakers use AAVE rather than SAE speech features.

227 We show that SAE occupies the active site in a manner similar to SAMe

228 The SAE method used age, race, gender, smoking, and poverty

229 eline systolic BP, and diastolic BP, and the SAE model had 8 variables including treatment interactio

230 The MACE/death and the SAE model had C statistics of 0.72 and 0.70, respectivel

231 l stimuli in a rapid manner, we assessed the SAE of smokers for genome-wide DNA methylation changes c

232 Using ESTs defining mRNAs derived from the SAE cell line, we identified lengthy and highly conserve

233 Because the expression of genes in the SAE cell line was prerequisite for their identification,

234 alters the DNA methylation patterning of the SAE and that, for some genes, these changes are associat

235 The applied KF component of the SAE was more difficult than the factual MCQ component (0

236 plied (9 KF cases) knowledge portions of the SAE, and the effect of examination preparation, examinat

237 acceptable annual risk (MAR) for each of the SAEs was calculated for various levels of clinical benef

238 These SAEs can simultaneously stabilize Pickering emulsions an

239 Thirteen SAEs were reported in relation to collection of IS, or 0

240 the percentages of death or life-threatening SAEs were lower in the bevacizumab arm (60% vs 75% of SA

241 to AEs was 3.5% and discontinuations due to SAEs was 1.3%, while in patients treated with SC adalimu

242 e aimed to understand antibodies reactive to SAEs and determine whether they recognize SAEs through t

243 Four patients underwent SAE after unsuccessful observation.

244 ormation about risk of YF disease vs vaccine SAEs.

245 etermine if the same was true in humans with SAE.

246 phisms were studied in Thai individuals with SAE (n = 18), with vaccination without neurological comp

247 ived unsuccessful nonsurgical treatment with SAE.

248 Es compared to 2 (20%) FMT participants with SAEs (both FMT unrelated; P = 0.02).